Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesRanked importance of outcomes of first-line versus repeated chemotherapy among ovarian cancer patients
Supportive Care in Cancer, 10/01/09
Beesley VL et al. – Women prioritise tumour response as the most important outcome of chemotherapy for ovarian cancer. This priority predominates in women with residual and relapsed disease despite declining likelihood of cure. Women may still hope for a cure while acknowledging their doctor's advice that their disease is incurable.
Methods- Women with newly diagnosed (74) or relapsed (48) ovarian cancer prospectively followed over 2 years
- Level of importance ascribed to four chemotherapy outcomes and beliefs about cure assessed
- Doctors independently specified intent of successive treatments
- Approximately half of newly diagnosed ovarian cancer patients ranked ‘tumour shrinkage (or decrease in blood levels of CA125)’ as ‘most important’ during first-line chemotherapy
- Approximately two thirds of all women whose disease had relapsed also ranked ‘tumour shrinkage’ as ‘most important’ during repeated chemotherapy
- Few women rated symptom relief or absence of side-effects as most important
- Patients' and doctors' belief about cure decreased over successive treatments, patients grew more optimistic relative to doctors over time
- Women's reports of advice by doctors about cure consistent with doctors' stated intents for repeat chemotherapy
- Discordance between doctors' actual treatment intent and patients' beliefs about cure increased from 24% at first-line to 83% by fourth-line chemotherapy
Today in Gynecologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Ovarian cancer screening and early detection
Women's Health, 11/04/09
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial
The Lancet, 11/23/09
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia
New England Journal of Medicine, 11/06/09
Sponsor
Article Search
Sponsor
Sponsor